Cardiac Risk Assessment: Beyond Traditional Calculators

Cardiac risk assessment combines a handful of traditional measurements with newer tools to estimate how likely you are to have a heart attack, stroke, or other cardiovascular event in the coming years. The standard approach starts with a risk calculator that plugs in your age, blood pressure, cholesterol, smoking status, and a few other variables, but those calculators have well-documented blind spots. Imaging, blood biomarkers, genetics, and even wearable devices are filling in the gaps, and the landscape is shifting fast enough that a risk estimate generated five years ago may have been built on a model that has already been replaced.

How Traditional Risk Calculators Work and Where They Fall Short

The original Framingham Risk Score, developed from decades of data collected in a Massachusetts town, was the first widely adopted tool for predicting heart disease. Framingham investigators eventually expanded their model into a global cardiovascular disease function that could estimate risk for coronary heart disease, stroke, claudication, and heart failure using a single set of inputs.

In the United States, the Pooled Cohort Equations (PCE) became the workhorse risk calculator recommended by major guidelines. The PCE estimates your ten-year risk of a first atherosclerotic cardiovascular event. But when researchers tested the PCE against a large, diverse, real-world population, they found it consistently overestimated risk, with moderate ability to distinguish who would and would not have an event. Discrimination, measured by a statistical metric called the C-statistic, ranged from about 0.68 to 0.74 across sex, racial, ethnic, and socioeconomic subgroups.¹ A C-statistic of 0.50 is coin-flip guessing; 1.0 is perfect. So values in the high 0.60s to low 0.70s mean the calculator is doing better than random, but not by a wide margin.

Recognizing these problems, the American Heart Association introduced a newer model called the PREVENT equations, designed to be better calibrated and to incorporate kidney function and other metabolic markers. In a head-to-head comparison, both the PREVENT base model and its fuller version showed much better calibration than the old PCE. The PCE overestimated ten-year risk by roughly double in some groups, while the PREVENT equations came much closer to observed event rates. Discrimination was similar between the two, hovering around a C-statistic of 0.74, though PREVENT showed gains in men and in Black adults specifically.² Better calibration matters because it determines whether a “10% risk” estimate actually corresponds to 10% of people having events, rather than, say, 5%.

Coronary Artery Calcium Scoring

If the risk calculator puts you somewhere in the middle, where the decision about whether to start a statin or intensify prevention is genuinely uncertain, a coronary artery calcium (CAC) scan can be one of the most useful tiebreakers available. A CAC scan is a low-dose, non-contrast CT that takes a few minutes and produces a score reflecting how much calcified plaque sits in your coronary arteries. A score of zero means no detectable calcification. Higher scores indicate more plaque burden.

The Multi-Ethnic Study of Atherosclerosis (MESA) found that among all the negative risk markers tested, a CAC score of zero was the strongest predictor of low risk. It produced the greatest downward shift in estimated cardiovascular risk, meaning people with a zero score could be reassured that their actual risk was lower than their calculator-based estimate suggested.³ On the flip side, adding calcium scoring to the Framingham Risk Score substantially improved discriminative power in asymptomatic people, refining classification not just in the intermediate-risk group but also in those at the extremes of traditional risk factor burden.⁴

In data from the Framingham Heart Study, CAC accurately reclassified about 85% of patients who had been sitting in the intermediate risk zone. Most of them were moved down to low risk with no events observed, while a smaller group was bumped up to high risk where event rates were meaningfully elevated.⁵ This makes CAC scoring especially helpful for the “maybe” group, the people whose ten-year risk lands around 5 to 10% and who could go either way on starting preventive medication.

CT Angiography and Stress Testing

When someone has symptoms like chest pain, the question shifts from long-term risk prediction to whether coronary artery disease is actually present right now. The traditional first-line test has been functional stress testing, either on a treadmill or with medications that simulate exercise while imaging the heart. Coronary CT angiography (CCTA) has emerged as a competing approach, using contrast dye and a CT scanner to visualize the arteries directly.⁶

A systematic review and meta-analysis comparing the two strategies found no significant differences in death or cardiac hospitalization. CCTA was linked to a modest reduction in heart attacks, but patients who got CCTA were also significantly more likely to be sent for invasive angiography and revascularization procedures, and more likely to be started on aspirin or statins.⁷ A large nationwide cohort study found that once baseline risk factors were balanced, CCTA was not associated with a lower rate of cardiac death or heart attack compared with functional testing.⁸

Where CCTA adds unique value is in characterizing plaque quality. It can identify so-called high-risk plaque features, like positive remodeling, low-attenuation plaque, napkin-ring signs, and spotty calcification. Research comparing these CT features against optical coherence tomography, which can see plaque at near-microscopic resolution, found that all four features correlated with thin-cap fibroatheroma, the type of plaque most prone to rupture.⁹ So CCTA offers anatomical information that stress testing simply cannot, even if the two strategies lead to broadly similar hard outcomes in clinical trials.

The trade-offs are real, though. CCTA involves radiation exposure, contrast dye injection, and carries the risk of incidental findings, spots on a lung or a thyroid nodule that may require follow-up scans and biopsies, leading to downstream testing that may not benefit the patient.¹⁰

Inflammation, Not Just Cholesterol

One of the most important shifts in cardiac risk thinking over the past decade has been the recognition that inflammation drives cardiovascular events independently of cholesterol. High-sensitivity C-reactive protein (hsCRP), a blood marker of systemic inflammation, has emerged as a powerful predictor, sometimes overshadowing cholesterol entirely.

A collaborative analysis of three large statin trials found that among patients already on statin therapy, residual inflammatory risk, measured by hsCRP, was strongly associated with future cardiovascular events, cardiovascular death, and death from any cause. The highest hsCRP group had more than two and a half times the cardiovascular mortality of the lowest group. By contrast, residual cholesterol risk, measured by LDL cholesterol levels, showed no significant relationship with major cardiovascular events and only a modest link to death.¹¹ The same pattern held in patients who could not tolerate statins: hsCRP strongly predicted events and death, while LDL cholesterol was a weaker and sometimes neutral predictor.¹²

This does not mean cholesterol is irrelevant. In the FOURIER trial, both LDL cholesterol and hsCRP were independently associated with cardiovascular outcomes.¹³ The point is that treating only cholesterol while ignoring persistent inflammation leaves substantial risk on the table. If you are on a statin and your cholesterol is well controlled but your hsCRP is still high, your residual risk is being driven more by inflammation than by lipids.

Lipoprotein(a), the Inherited Risk Factor Most People Have Never Heard Of

Standard lipid panels measure total cholesterol, LDL, HDL, and triglycerides. They do not typically measure lipoprotein(a), usually written as Lp(a), a particle that looks like LDL but carries extra inflammatory and clot-promoting baggage. Elevated Lp(a) is genetically determined, largely unaffected by diet or exercise, and affects a sizable fraction of the population.

Genetic evidence strongly supports a causal role for Lp(a) in cardiovascular disease. Both elevated blood levels and the genetic variants that drive those levels are associated with coronary disease, making Lp(a) one of the strongest genetically transmitted risk factors for heart disease identified so far.¹⁴ Mechanistic, observational, and genetic studies also link elevated Lp(a) to peripheral arterial disease, aortic valve stenosis, and likely ischemic stroke.¹⁵ It is an independent risk driver, meaning it contributes to cardiovascular events on top of whatever your LDL, blood pressure, and other factors are doing.¹⁶

Because Lp(a) is not on a standard lipid panel, many people with high levels never find out. Current guidelines recommend checking it at least once in a lifetime, and there are drugs in advanced clinical trials designed to lower it substantially.

High-Sensitivity Troponin in People Without Symptoms

You may associate troponin with a heart attack blood test. When someone shows up to an emergency room with chest pain, a spike in cardiac troponin confirms myocardial injury. But high-sensitivity assays can now detect tiny amounts of troponin circulating in apparently healthy people, and those trace levels carry significant prognostic weight.

In the Atherosclerosis Risk in Communities (ARIC) study, participants without known heart disease whose troponin T levels were in the highest measurable category had dramatically increased risks compared to those with undetectable levels: roughly double the risk of coronary events, nearly eight times the risk of fatal coronary disease, about four times the risk of death from any cause, and about six times the risk of heart failure hospitalization. Adding troponin to traditional risk factors improved risk prediction to a degree comparable to adding NT-proBNP, a well-established heart failure biomarker, and better than adding hsCRP.¹⁷

A large European consortium study using high-sensitivity troponin I found similar results for heart failure prediction specifically, and derived sex-specific cutoff values for identifying people at elevated risk: roughly 2.6 ng/L for women and 4.2 ng/L for men.¹⁸ These thresholds are far below what would trigger concern in an emergency setting. The signal they pick up is subclinical myocardial stress, low-grade cardiac damage happening silently.

Polygenic Risk Scores

Your DNA contains thousands of small genetic variants that individually have a trivial effect on heart disease risk but collectively can add up to a meaningful signal. A polygenic risk score (PRS) aggregates these variants into a single number. The question is whether that number tells you anything your doctor cannot already figure out from your blood pressure, cholesterol, and family history.

In European adults with high blood pressure, adding a PRS to a traditional clinical risk score improved the C-statistic from 0.72 to 0.74 and resulted in about 10% net reclassification improvement overall.¹⁹ Separately, a cross-sectional study of an Austrian cohort found that PRS improved the ability to predict significant coronary artery calcium beyond the SCORE2 risk calculator alone, with particularly strong improvements in women and in people at low-to-moderate clinical risk.²⁰

The improvements are statistically real but still modest. Where polygenic scores seem most promising is in younger people and those whose traditional risk factors have not yet declared themselves. If you are 40, your blood pressure is normal, and your cholesterol is borderline, a high PRS might be the nudge that triggers earlier lifestyle intervention or closer follow-up. But the technology is still not part of routine clinical care for most people, partly because the scores were developed primarily in European populations and transfer imperfectly to other ancestries.

Pregnancy Complications as a Cardiac Risk Flag

For women, the obstetric history contains cardiovascular clues that risk calculators traditionally ignore. Preeclampsia, gestational hypertension, gestational diabetes, preterm birth, and stillbirth are not just pregnancy problems. They leave lasting vascular and metabolic footprints.²¹

A large meta-analytic review found that preeclampsia roughly tripled the odds of later cardiovascular disease, while gestational hypertension, placental abruption, gestational diabetes, and preterm birth each raised the odds by about 50 to 80%.²² A nationwide cohort study confirmed these associations for cardiovascular mortality specifically, with an adjusted hazard ratio of about 1.8 for preterm birth and about 3.1 for stillbirth, even after accounting for smoking, overweight, and other comorbidities.²³

The newer PREVENT risk equations now incorporate pregnancy history as an optional input, which is a step forward. But many women and their physicians are still unaware that a complicated pregnancy decades earlier is relevant to cardiac risk today. If you had preeclampsia or delivered preterm, that information belongs in every cardiovascular risk conversation you have going forward.

Peripheral Vascular Markers

You do not always need to image the heart directly to assess cardiovascular risk. Two inexpensive, office-based tests can reveal a lot about the state of your arteries more broadly.

The ankle-brachial index (ABI), which compares blood pressure at your ankle to blood pressure in your arm, is a simple screen for peripheral artery disease. In a population-based study with 13 years of follow-up, every 0.1-unit decrease in ABI was associated with a 22% increase in heart attack risk and roughly a 32 to 35% increase in cardiovascular and total mortality.²⁴ The same study found that the number of arterial sites affected by plaque, assessed by ultrasound of the carotid and femoral arteries, was an equally strong predictor.

Carotid ultrasound, which can measure the thickness of the artery wall and spot plaques directly, provides complementary information. When combined with ABI, it offers useful insight into coronary disease complexity.²⁵ Screening for carotid plaques may enhance traditional risk stratification strategies for coronary artery disease, particularly in people for whom deciding whether to pursue further testing is unclear.²⁶

Wearable Devices and AI-Driven Screening

Consumer smartwatches are now capable of detecting atrial fibrillation, a major risk factor for stroke, with impressive accuracy. A systematic review and diagnostic meta-analysis covering more than 17,000 patients found overall sensitivity of 95% and specificity of 97% across devices. The Apple Watch achieved about 94% sensitivity and 97% specificity, while Samsung devices reached 97% sensitivity and 96% specificity.²⁷ Wearable patches are also showing strong performance and may outperform traditional Holter monitors in long-term monitoring.²⁸

On the artificial intelligence front, researchers have developed algorithms that extract cardiovascular risk information from routine 12-lead electrocardiograms, something standard ECG interpretation cannot do. An AI-enabled platform called AIRE demonstrated the ability to predict atherosclerotic cardiovascular disease in people without known disease (C-index around 0.70), and showed stronger performance predicting heart failure (C-index about 0.79) and ventricular arrhythmia (C-index about 0.76).²⁹ This is notable because it means an ECG recorded during a routine checkup could, in theory, be fed through an AI model to flag elevated risk before any symptoms appear. External validation in healthier volunteer populations showed reduced but still meaningful performance, which is expected when moving from clinical datasets to the general population.

Risk Factors That Rarely Make It Into Calculators

Several cardiovascular risk drivers sit outside the variables plugged into standard models. Night-shift work, for example, has been linked to a roughly 10% excess risk of diabetes, about a 25% increase in risk of being overweight (reaching 38% among dedicated night-shift workers), and an estimated 30% excess risk of hypertension when night periods are included in rotating schedules.³⁰ These downstream metabolic effects feed into heart disease risk, but no mainstream calculator asks about shift-work exposure.

Social determinants of health, including income, education, and chronic psychosocial stress, shape cardiovascular outcomes substantially. Lower socioeconomic status is associated with greater exposure to poor nutrition, limited healthcare access, and harmful environmental exposures like air pollution, all of which promote the oxidative stress and inflammation that underpin cardiovascular disease.³¹

Emerging evidence also links gut microbial metabolism to cardiovascular risk. When intestinal bacteria digest dietary phosphatidylcholine, found in red meat and eggs, they produce trimethylamine N-oxide (TMAO), a metabolite associated with increased risk of major adverse cardiovascular events.³² A meta-analysis of prospective studies confirmed that elevated TMAO and its precursors were associated with increased risks of major cardiovascular events and death independently of traditional risk factors.³³ TMAO testing is not yet standard, but it illustrates how much risk information exists beyond the variables that current calculators capture.

Cardiac Risk Assessment Before Cancer Treatment

One population that needs specialized risk assessment is people about to start cancer therapy. Many chemotherapy agents, targeted therapies, and radiation regimens are known to damage the heart, and the risk varies widely depending on the treatment, dose, and each patient’s pre-existing cardiovascular profile. A position statement from the European Society of Cardiology’s Cardio-Oncology Study Group outlines practical tools for stratifying cancer patients into low, medium, high, and very high risk of cardiovascular complications before treatment begins.³⁴

This kind of pre-treatment stratification can guide decisions about whether to use a less cardiotoxic alternative regimen, how aggressively to manage blood pressure and cholesterol before chemo starts, and how closely to monitor heart function during and after treatment. Autoimmune diseases like rheumatoid arthritis add another layer. Patients with rheumatoid arthritis who show signs of metabolic liver dysfunction, assessed by a simple blood-test score, tend to have thicker carotid artery walls, higher blood pressure, and elevated atherogenic lipid particles, all suggesting accelerated cardiovascular risk that would not necessarily show up on a standard risk calculator.³⁵ These comorbidity-driven risk layers are becoming increasingly important as clinicians recognize that cardiovascular disease does not develop in isolation from the rest of the body’s pathology.